LONSARIS

Serial Number 85619283
606

Registration Progress

Application Filed
May 8, 2012
Under Examination
Dec 18, 2012
Approved for Publication
Oct 23, 2012
Published for Opposition
Oct 23, 2012
Registered

Trademark Image

LONSARIS

Basic Information

Serial Number
85619283
Filing Date
May 8, 2012
Published for Opposition
October 23, 2012
Abandonment Date
January 18, 2016
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 18, 2016
Classes
005

Rights Holder

ALKERMES PHARMA IRELAND LIMITED

03
Address
CONNAUGHT HOUSE
1 BURLINGTON ROAD
DUBLIN 4
IE

Ownership History

Alkermes, Inc.

Original Applicant
03
Waltham, MA

ALKERMES PHARMA IRELAND LIMITED

New Owner Before Publication #1
03
DUBLIN 4 IE

ALKERMES PHARMA IRELAND LIMITED

Owner at Publication
03
DUBLIN 4 IE

Legal Representation

Attorney
Norman J. Rich

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

41 events
Date Code Type Description Documents
Jan 19, 2016 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Jan 18, 2016 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
May 6, 2015 EXRA O NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED Loading...
May 5, 2015 EX5G S SOU EXTENSION 5 GRANTED Loading...
Apr 27, 2015 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 27, 2015 EXT5 S SOU EXTENSION 5 FILED Loading...
Jan 28, 2015 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 28, 2015 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Nov 25, 2014 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 24, 2014 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 17, 2014 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 17, 2014 EXT4 S SOU EXTENSION 4 FILED Loading...
Apr 24, 2014 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 23, 2014 EX3G S SOU EXTENSION 3 GRANTED Loading...
Apr 18, 2014 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 18, 2014 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 13, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 12, 2013 EX2G S SOU EXTENSION 2 GRANTED Loading...
Dec 9, 2013 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 9, 2013 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Nov 1, 2013 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 1, 2013 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 15, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 13, 2013 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 13, 2013 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 13, 2013 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 18, 2012 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 23, 2012 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 23, 2012 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 3, 2012 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 17, 2012 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Sep 14, 2012 ALIE A ASSIGNED TO LIE Loading...
Sep 5, 2012 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Sep 5, 2012 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Sep 5, 2012 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Sep 5, 2012 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Sep 5, 2012 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 29, 2012 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 22, 2012 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
May 15, 2012 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 11, 2012 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Translation
The wording "LONSARIS" has no meaning in a foreign language.

Classification

International Classes
005